Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

doi:10.1016/j.medj.2023.07.007

. 2023 Oct 13;4(10):664-667.

doi: 10.1016/j.medj.2023.07.007.

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Timothée Bruel¹, Lou-Léna Vrignaud², Françoise Porrot³, Isabelle Staropoli³, Delphine Planas⁴, Florence Guivel-Benhassine³, Julien Puech⁵, Matthieu Prot⁶, Sandie Munier⁶, William Henry Bolland⁷, Cathia Soulié⁸, Karen Zafilaza⁸, Clovis Lusivika-Nzinga⁹, Marie-Laure Meledge⁹, Céline Dorival⁹, Diana Molino¹⁰, Hélène Péré¹¹, Youri Yordanov¹², Etienne Simon-Lorière¹³, David Veyer¹¹, Fabrice Carrat¹⁴, Olivier Schwartz⁴, Anne-Geneviève Marcelin⁸, Guillaume Martin-Blondel¹⁵; ANRS 0003S CoCoPrev Study Group¹⁰

Collaborators, Affiliations

Collaborators

ANRS 0003S CoCoPrev Study Group:
Magalie Garcia, Valentin Giraud, Agathe Metais, Fance Cazenave-Roblot, Jean-Philippe Martellosio Anne-Marie Ronchetti, Thomas Gabas, Naima Hadjadj, Célia Salanoubat, Amélie Chabrol, Pierre Housset, Agathe Pardon, Anne-Laure Faucon, Valérie Caudwell, Latifa Hanafi Roland Liblau, Laurent Alric, Grégory Pugnet, Morgane Mourguet, Eva Bories, Delphine Bonnet, Sandrine Charpentier, Pierre Delobel, Alexa Debard, Colleen Beck, Xavier Boumaza, Stella Rousset Fanny Lanternier, Claire Delage, Elisabete Gomes Pires, Morgane Cheminant, Nathalie Chavarot Anthony Chauvin, Xavier Eyer Véronique Delcey Simon Bessis, Mélanie Cresta, Romain Gueneau Pélagie Thibaut, Marine Nadal, Martin Siguier, Marwa Bachir, Christia Palacios Valérie Pourcher, Cléa Melenotte, Antoine Faycal, Vincent Berot, Cécile Brin, Siham Djebara, Karen Zafilaza, Stéphane Marot, Sophie Sayon, Vincent Leducq, Isabelle Malet, Elisa Teyssou, Adélie Gothland Karine Lacombe, Yasmine Abi Aad, Thibault Chiarabini, Raynald Feliho, Nadia Valin, Fabien Brigant, Julien Boize, Pierre-Clément Thiébaud, Marie Moreau, Charlotte Billard Nathalie De Castro, Geoffroy Liégeon, Blandine Denis, Jean-Michel Molina, Lucia Etheve André Cabié, Sylvie Abel, Ornella Cabras, Karine Guitteaud, Sandrine Pierre- François Vincent Dubee, Diama Ndiaye, Jonathan Pehlivan, Michael Phelippeau, Rafael Mahieu Alexandre Duvignaud, Thierry Pistone, Arnaud Desclaux, Didier Neau, Charles Cazanave Jean-François Faucher, Benjamin Festou, Magali Dupuy-Grasset, Véronique Loustaud-Ratti, Delphine Chainier Nathan Peiffer-Smadja, Christophe Choquet, Olivia Da Conceicao, Michael Thy, Lio Collas, Cindy Godard, Donia Bouzid, Vittiaroat Ing, Laurent Pereira, Thomas Pavlowsky, Camille RavautAntoine Asquier-Khati, David Boutoille, Marie Chauveau, Colin Deschanvres, François Raffi Audrey Le Bot, Marine Cailleaux, François Benezit, Anne Maillard, Benoit Hue, Pierre Tattevin François Coustilleres, Claudia Carvalho-Schneider, Simon Jamard, Laeticia Petit, Karl Stefic Natacha Mrozek, Clément Theis, Magali Vidal, Léo Sauvat, Delphine Martineau Benjamin Lefèvre, Guillaume Baronnet, Agnès Didier Florence Ader, Thomas Perpoint, Anne Conrad, Paul Chabert, Pierre Chauvelot Aurélie Martin, Paul Loubet, Julien Mazet, Romaric Larcher, Didier Laureillard Mathilde Devaux Jérôme Frey, Amos Woerlen, Aline Remillon, Laure Absensur-Vuillaume, Pauline Bouquet Albert Trinh-Duc, Patrick Rispal Philippe Petua, Julien Carillo Aurore Perrot, Karen Delavigne, Pierre Cougoul, Jérémie Dion, Odile Rauzy Mathieu Blot, Thibault Sixt, Florian Moretto, Carole Charles, Lionel Piroth Sophie Circosta, Lydia Leger, Arulvani Arulananthan, Carine Lascoux, Pascaline Valérie, Leia Becam Yazdan Yazdanpanah, Ventzislava Petrov-Sanchez, Alpha Diallo, Soizic Le Mestre, Guillaume Le Meut Isabelle Goderel, Frédéric Chau, Brahim Soltana, Jessica Chane Tang, Jérémie Guedj, Yvanie Caille

Affiliations

¹ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France. Electronic address: timothee.bruel@pasteur.fr.
² Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Sorbonne Université, Paris, France.
³ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
⁴ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France.
⁵ Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
⁶ G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
⁷ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; École Doctorale BioSPC 562, Université de Paris, Paris, France.
⁸ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Virology Department, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
⁹ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France.
¹⁰ INSERM-ANRS Maladies Infectieuses Emergentes, 75015 Paris, France.
¹¹ Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France; Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France.
¹² Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Hôpital Saint-Antoine, Service d'Accueil des Urgences, Assistance Publique - Hôpitaux de Paris, AP-HP, Sorbonne Université, Paris, France.
¹³ G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France; Institut Pasteur, Université Paris Cité, National Reference Center for viruses of respiratory infections, Paris, France.
¹⁴ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Hôpital Saint-Antoine, santé publique, APHP Paris, Paris, France.
¹⁵ Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM, Université Toulouse III., Toulouse, France. Electronic address: martin-blondel.g@chu-toulouse.fr.

PMID: 37837962
PMCID: PMC11232389
DOI: 10.1016/j.medj.2023.07.007

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Timothée Bruel et al. Med. 2023.

. 2023 Oct 13;4(10):664-667.

doi: 10.1016/j.medj.2023.07.007.

Authors

Collaborators

ANRS 0003S CoCoPrev Study Group:
Magalie Garcia, Valentin Giraud, Agathe Metais, Fance Cazenave-Roblot, Jean-Philippe Martellosio Anne-Marie Ronchetti, Thomas Gabas, Naima Hadjadj, Célia Salanoubat, Amélie Chabrol, Pierre Housset, Agathe Pardon, Anne-Laure Faucon, Valérie Caudwell, Latifa Hanafi Roland Liblau, Laurent Alric, Grégory Pugnet, Morgane Mourguet, Eva Bories, Delphine Bonnet, Sandrine Charpentier, Pierre Delobel, Alexa Debard, Colleen Beck, Xavier Boumaza, Stella Rousset Fanny Lanternier, Claire Delage, Elisabete Gomes Pires, Morgane Cheminant, Nathalie Chavarot Anthony Chauvin, Xavier Eyer Véronique Delcey Simon Bessis, Mélanie Cresta, Romain Gueneau Pélagie Thibaut, Marine Nadal, Martin Siguier, Marwa Bachir, Christia Palacios Valérie Pourcher, Cléa Melenotte, Antoine Faycal, Vincent Berot, Cécile Brin, Siham Djebara, Karen Zafilaza, Stéphane Marot, Sophie Sayon, Vincent Leducq, Isabelle Malet, Elisa Teyssou, Adélie Gothland Karine Lacombe, Yasmine Abi Aad, Thibault Chiarabini, Raynald Feliho, Nadia Valin, Fabien Brigant, Julien Boize, Pierre-Clément Thiébaud, Marie Moreau, Charlotte Billard Nathalie De Castro, Geoffroy Liégeon, Blandine Denis, Jean-Michel Molina, Lucia Etheve André Cabié, Sylvie Abel, Ornella Cabras, Karine Guitteaud, Sandrine Pierre- François Vincent Dubee, Diama Ndiaye, Jonathan Pehlivan, Michael Phelippeau, Rafael Mahieu Alexandre Duvignaud, Thierry Pistone, Arnaud Desclaux, Didier Neau, Charles Cazanave Jean-François Faucher, Benjamin Festou, Magali Dupuy-Grasset, Véronique Loustaud-Ratti, Delphine Chainier Nathan Peiffer-Smadja, Christophe Choquet, Olivia Da Conceicao, Michael Thy, Lio Collas, Cindy Godard, Donia Bouzid, Vittiaroat Ing, Laurent Pereira, Thomas Pavlowsky, Camille RavautAntoine Asquier-Khati, David Boutoille, Marie Chauveau, Colin Deschanvres, François Raffi Audrey Le Bot, Marine Cailleaux, François Benezit, Anne Maillard, Benoit Hue, Pierre Tattevin François Coustilleres, Claudia Carvalho-Schneider, Simon Jamard, Laeticia Petit, Karl Stefic Natacha Mrozek, Clément Theis, Magali Vidal, Léo Sauvat, Delphine Martineau Benjamin Lefèvre, Guillaume Baronnet, Agnès Didier Florence Ader, Thomas Perpoint, Anne Conrad, Paul Chabert, Pierre Chauvelot Aurélie Martin, Paul Loubet, Julien Mazet, Romaric Larcher, Didier Laureillard Mathilde Devaux Jérôme Frey, Amos Woerlen, Aline Remillon, Laure Absensur-Vuillaume, Pauline Bouquet Albert Trinh-Duc, Patrick Rispal Philippe Petua, Julien Carillo Aurore Perrot, Karen Delavigne, Pierre Cougoul, Jérémie Dion, Odile Rauzy Mathieu Blot, Thibault Sixt, Florian Moretto, Carole Charles, Lionel Piroth Sophie Circosta, Lydia Leger, Arulvani Arulananthan, Carine Lascoux, Pascaline Valérie, Leia Becam Yazdan Yazdanpanah, Ventzislava Petrov-Sanchez, Alpha Diallo, Soizic Le Mestre, Guillaume Le Meut Isabelle Goderel, Frédéric Chau, Brahim Soltana, Jessica Chane Tang, Jérémie Guedj, Yvanie Caille

Affiliations

¹ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France. Electronic address: timothee.bruel@pasteur.fr.
² Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Antiviral Activities of Antibodies Group, Université Paris Cité, CNRS UMR3569, Paris, France; Sorbonne Université, Paris, France.
³ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.
⁴ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; Vaccine Research Institute, Créteil, France.
⁵ Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France.
⁶ G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France.
⁷ Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France; École Doctorale BioSPC 562, Université de Paris, Paris, France.
⁸ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Virology Department, Pitié-Salpêtrière Hospital, Sorbonne University, 75013 Paris, France.
⁹ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France.
¹⁰ INSERM-ANRS Maladies Infectieuses Emergentes, 75015 Paris, France.
¹¹ Laboratoire de Virologie, Service de Microbiologie, Hôpital Européen Georges Pompidou, Paris, France; Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France.
¹² Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Hôpital Saint-Antoine, Service d'Accueil des Urgences, Assistance Publique - Hôpitaux de Paris, AP-HP, Sorbonne Université, Paris, France.
¹³ G5 Evolutionary Genomics of RNA Viruses, Institut Pasteur, Université Paris Cité, Paris, France; Institut Pasteur, Université Paris Cité, National Reference Center for viruses of respiratory infections, Paris, France.
¹⁴ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et Santé Publique, 75012 Paris, France; Hôpital Saint-Antoine, santé publique, APHP Paris, Paris, France.
¹⁵ Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM, Université Toulouse III., Toulouse, France. Electronic address: martin-blondel.g@chu-toulouse.fr.

PMID: 37837962
PMCID: PMC11232389
DOI: 10.1016/j.medj.2023.07.007

Abstract

Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and antibody-dependent cellular cytotoxicity of BQ.1.1 and XBB.1.5. Therefore, sotrovimab may remain a therapeutic option against these variants.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest T.B. and O.S. have a pending patent application for an anti-RBD mAb not used in this study (PCT/FR2021/070522).

Cited by

Comparison of Dual Monoclonal Antibody Therapies for COVID-19 Evolution: A Multicentric Retrospective Study.
Zafilaza K, Bellet J, Truffot A, Foulongne V, Onambele MM, Salmona M, Vellas C, Périllaud-Dubois C, Mirand A, André-Garnier E, Alidjinou EK, Brichler S, Fenaux H, Bouvier-Alias M, Hartard C, Dorival C, Carrat F, Marcelin AG, Stefic K, Soulie C. Zafilaza K, et al. Viruses. 2024 Sep 29;16(10):1542. doi: 10.3390/v16101542. Viruses. 2024. PMID: 39459877 Free PMC article.
Clinical features of and severity risk factors for COVID-19 in adults during the predominance of SARS-CoV-2 XBB variants in Okinawa, Japan.
Ideguchi S, Miyagi K, Kami W, Tasato D, Higa F, Maeshiro N, Nagamine S, Nakamura H, Kinjo T, Nakamatsu M, Haranaga S, Tokushige A, Ueda S, Fujita J, Yamamoto K. Ideguchi S, et al. PLoS One. 2024 Oct 31;19(10):e0309808. doi: 10.1371/journal.pone.0309808. eCollection 2024. PLoS One. 2024. PMID: 39480756 Free PMC article.
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Boland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S; COVID-SER study group; Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Planas D, et al. bioRxiv [Preprint]. 2024 Feb 9:2023.11.20.567873. doi: 10.1101/2023.11.20.567873. bioRxiv. 2024. Update in: Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7 PMID: 38045308 Free PMC article. Updated. Preprint.
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S, Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Planas D, et al. Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7. Nat Commun. 2024. PMID: 38480689 Free PMC article.
Akaluc bioluminescence offers superior sensitivity to track in vivo dynamics of SARS-CoV-2 infection.
Tamura T, Ito H, Torii S, Wang L, Suzuki R, Tsujino S, Kamiyama A, Oda Y, Tsuda M, Morioka Y, Suzuki S, Shirakawa K, Sato K, Yoshimatsu K, Matsuura Y, Iwano S, Tanaka S, Fukuhara T. Tamura T, et al. iScience. 2024 Mar 29;27(5):109647. doi: 10.1016/j.isci.2024.109647. eCollection 2024 May 17. iScience. 2024. PMID: 38638572 Free PMC article.

See all "Cited by" articles

References

1. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, et al. (2022). Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. New Engl J Med 388, 89–91. 10.1056/nejmc2214302. - DOI - PMC - PubMed
1. Wu MY, Carr EJ, Harvey R, Mears HV, Kjaer S, Townsley H, Hobbs A, Ragno M, Herman LS, Adams L, et al. (2023). WHO’s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed. Lancet Lond Engl 400, 2193–2196. 10.1016/s0140-6736(22)01938-9. - DOI - PMC - PubMed
1. Mazzaferri F, Mirandola M, Savoldi A, Nardo PD, Morra M, Tebon M, Armellini M, Luca GD, Calandrino L, Sasset L, et al. (2022). Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Elife 11, e79639. 10.7554/elife.79639. - DOI - PMC - PubMed
1. Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, Schultze A, Mahalingasivam V, Parker EPK, Hulme WJ, et al. (2022). Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. Bmj 379, e071932. 10.1136/bmj-2022-071932. - DOI - PMC - PubMed
1. Schmidt P, Narayan K, Li Y, Kaku CI, Brown ME, Champney E, Geoghegan JC, Vásquez M, Krauland EM, Yockachonis T, et al. (2023). Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci Transl Med 15, eadg2783. 10.1126/scitranslmed.adg2783. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

U01 AI151758/AI/NIAID NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, et al. (2022). Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. New Engl J Med 388, 89–91. 10.1056/nejmc2214302. - DOI - PMC - PubMed

[2] Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, et al. (2022). Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. New Engl J Med 388, 89–91. 10.1056/nejmc2214302. - DOI - PMC - PubMed

[3] Wu MY, Carr EJ, Harvey R, Mears HV, Kjaer S, Townsley H, Hobbs A, Ragno M, Herman LS, Adams L, et al. (2023). WHO’s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed. Lancet Lond Engl 400, 2193–2196. 10.1016/s0140-6736(22)01938-9. - DOI - PMC - PubMed

[4] Wu MY, Carr EJ, Harvey R, Mears HV, Kjaer S, Townsley H, Hobbs A, Ragno M, Herman LS, Adams L, et al. (2023). WHO’s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed. Lancet Lond Engl 400, 2193–2196. 10.1016/s0140-6736(22)01938-9. - DOI - PMC - PubMed

[5] Mazzaferri F, Mirandola M, Savoldi A, Nardo PD, Morra M, Tebon M, Armellini M, Luca GD, Calandrino L, Sasset L, et al. (2022). Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Elife 11, e79639. 10.7554/elife.79639. - DOI - PMC - PubMed

[6] Mazzaferri F, Mirandola M, Savoldi A, Nardo PD, Morra M, Tebon M, Armellini M, Luca GD, Calandrino L, Sasset L, et al. (2022). Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern. Elife 11, e79639. 10.7554/elife.79639. - DOI - PMC - PubMed

[7] Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, Schultze A, Mahalingasivam V, Parker EPK, Hulme WJ, et al. (2022). Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. Bmj 379, e071932. 10.1136/bmj-2022-071932. - DOI - PMC - PubMed

[8] Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, Schultze A, Mahalingasivam V, Parker EPK, Hulme WJ, et al. (2022). Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform. Bmj 379, e071932. 10.1136/bmj-2022-071932. - DOI - PMC - PubMed

[9] Schmidt P, Narayan K, Li Y, Kaku CI, Brown ME, Champney E, Geoghegan JC, Vásquez M, Krauland EM, Yockachonis T, et al. (2023). Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci Transl Med 15, eadg2783. 10.1126/scitranslmed.adg2783. - DOI - PubMed

[10] Schmidt P, Narayan K, Li Y, Kaku CI, Brown ME, Champney E, Geoghegan JC, Vásquez M, Krauland EM, Yockachonis T, et al. (2023). Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci Transl Med 15, eadg2783. 10.1126/scitranslmed.adg2783. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Collaborators

Affiliations

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources